| Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. | |
| | |
MedLine Citation:
|
PMID: 12767094 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: S100beta protein is expressed constitutively by brain astrocytes. Elevated S100beta levels in cerebrospinal fluid and serum reported after head trauma, subarachnoid hemorrhage, and stroke were correlated with the extent of brain damage. Because elevated serum S100beta also was shown to indicate blood-brain barrier (BBB) dysfunction in the absence of apparent brain injury, it remains unclear whether elevation of serum levels of S100beta reflect BBB dysfunction, parenchymal damage, or both. METHODS: The authors conducted a prospective study of serum S100beta levels in six patients who underwent hyperosmotic BBB disruption (BBBD) with intraarterial chemotherapy for primary central nervous system lymphoma. In addition, 53 serum S100beta samples were measured in 51 patients who had a variety of primary or metastatic brain lesions at the time of neuroimaging. RESULTS: S100beta was correlated directly with the degree of clinical and radiologic signs of BBBD in patients who were enrolled in the hyperosmotic study. In patients with neoplastic brain lesions, gadolinium enhancement on a magnetic resonance image was correlated with elevated S100beta levels (n = 45 patients; 0.16 +/- 0.1 microg/L; mean +/- standard error of the mean) versus nonenhancing scans (n = 8 patients; 0.069 +/- 0.04 microg/L). Primary brain tumors (n = 8 patients; 0.12 +/- 0.08) or central nervous system metastases also presented with elevated serum S100beta levels (n = 27 patients; 0.14 +/- 0.34). Tumor volume was correlated with serum S100beta levels only in patients with vestibular schwannoma (n = 6 patients; 0.13 +/- 0.10 microg/L) but not in patients with other brain lesions. CONCLUSIONS: S100beta was correlated directly with the extent and temporal sequence of hyperosmotic BBBD, further suggesting that S100beta is a marker of BBB function. Elevated S100beta levels may indicate the presence of radiologically detectable BBB leakage. Larger prospective studies may better determine the true specificity of S100beta as a marker for BBB function and as an early detection or follow-up marker of brain tumors. |
| | |
Authors:
|
Andrew A Kanner; Nicola Marchi; Vincent Fazio; Marc R Mayberg; Michael T Koltz; Vitaly Siomin; Glen H J Stevens; Thomas Masaryk; Barbara Aumayr; Barbara Ayumar; Michael A Vogelbaum; Gene H Barnett; Damir Janigro |
Related Documents
:
|
20012544 - The thalamic ultrastructural abnormalities in paroxysmal kinesigenic choreoathetosis: a... 3481474 - Eye motility dysfunction in chronic primary fibromyalgia with dysesthesia. 4073844 - Hypoglycemia masquerading as cerebrovascular disease (hypoglycemic hemiplegia). 2411514 - Is the auditory brain-stem response (abr) effective in the assessment of post-traumatic... 6776004 - Pancreatitis in association with hypercalcemia in patients receiving total parenteral n... 10601404 - Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is th... |
Publication Detail:
|
Type: Journal Article; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Cancer Volume: 97 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 2003 Jun |
Date Detail:
|
Created Date: 2003-05-26 Completed Date: 2003-06-20 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 2806-13 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright 2003 American Cancer Society. |
Affiliation:
|
Brain Tumor Institute, The Cleveland Clinic, Ohio 44195, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Biological Markers / blood* Blood-Brain Barrier / physiology* Brain Neoplasms / blood, diagnosis* Female Humans Magnetic Resonance Imaging Male Middle Aged Nerve Growth Factors / blood* Prospective Studies S100 Proteins / blood* |
| Grant Support | |
ID/Acronym/Agency:
|
HL51614/HL/NHLBI NIH HHS; NS38195/NS/NINDS NIH HHS; NS43284/NS/NINDS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Nerve Growth Factors; 0/S-100 calcium-binding protein beta subunit; 0/S100 Proteins |
| Comments/Corrections | |
Erratum In:
|
Cancer. 2006;107(9 No 1):2314 Note: Ayumar, Barbara [corrected to Aumayr, Barbara] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: cDNA microarray analysis of gene expression in pathologic Stage IA nonsmall cell lung carcinomas.
Next Document: Cyclooxygenase-2 expression in human pituitary tumors.